Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516771 | 1.00 | ALK (0.49) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4516776 | 1.00 | ALK (0.49) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4505646 | 0.93 | ALK (0.50) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4505637 | 0.93 | ALK (0.50) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4516583 | 0.91 | CDK9 (0.46) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4516590 | 0.91 | CDK9 (0.46) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4516589 | 0.91 | CDK9 (0.46) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4505840 | 0.89 | ALK (0.47) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4505843 | 0.89 | ALK (0.47) | ALKMEN1KMT2ARXFP1PAK4 | |
| SCHEMBL4505831 | 0.89 | ALK (0.47) | ALKMEN1KMT2ARXFP1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | ALK 619/4885MEN1 4237/4885KMT2A 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.